Biopharmaceutics

There's a company called Tamarin Bio that launched on Hacker News earlier this year.

Their pitch is, Biopharma companies use our library of leading open-source models to design new medicines computationally.

That's a real business, serving real customers, doing real science.

And nobody tweets about it.

You can block a protein.

I'm going to Japan next month, or sorry, next year, early next year to talk to Torridge and Biopharma.

They block a protein called USAG1.

When you block it, your teeth, your third, fourth, fifth set of teeth start to grow.

And he analyzed all of the quarter two twenty twenty-six CRO results and the, and the earnings and their earnings calls so that we don't have to, myself included.

[chuckles] I listened to a couple, but he dissected all of them, and he came out with his report.

I'll have links to that underneath this video.

There's also from JPMorgan, they have their quarterly two twenty twenty-six biopharma and med tech report, uh, PDFs that you can download.

I'm gonna have links to both of those underneath.

I'll have the link where you can get both of those underneath this video and in the show notes.

Uh, uh, but there are, there's a lot of mergers and acquisitions, just like in big pharma, uh, when it comes to The larger, I guess, more established tech vendors that are out there.

So we're gonna connect all these singles.